The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility

Transfusion Medicine Reviews

Volumn 17, Issue 1, 2003, Pages 57-68

  Lozano, Miguel ^a,b,c   Cid, Joan ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Tissue Bank   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BIOAVAILABILITY; BLOOD GROUP ABO INCOMPATIBILITY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ECONOMICS; ERYTHROCYTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEASUREMENT; PREGNANCY; RECIPIENT; REVIEW; RHESUS INCOMPATIBILITY; RISK FACTOR; THROMBOCYTE TRANSFUSION;

EID: 0037228546     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2003.50003     Document Type: Review

References (92)

1. Klein E, Djerassi I, Farber S: Maintenance of normal platelet levels in recipients of multiple transfusions of platelets from incompatible blood. Proceedings of the VIIth Congress of the International Society of Hematology. Rome, Italy, September 7-13, 1958 (abstr 957)
2. Djerassi I, Farber S, Evans AE: Transfusion of fresh platelet concentrates to patients with secondary thrombocytopenia. N Engl J Med 268:221-226, 1963
3. Gurevitch J, Nelken D: ABO groups in blood platelets. Nature 173:356, 1954 (letter)
4. Dunstan RA, Simpson MB, Knowles RW, et al: The origin of ABH antigens on human platelets. Blood 65:615-619, 1985
5. Santoso S, Kiefel V, Mueller-Eckhardt C: Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemost 65:196-201, 1991
6. 2 individuals. Transfusion 28:456-459, 1988
7. Ogasawara K, Ueki J, Takenaka M, et al: Study on the expression of ABH antigens on platelets. Blood 82:993-999, 1993
8. Dunstan RA, Mansbach CM: Biochemical characterisation of A blood group activity on human platelets. Vox Sang 49:149-153, 1985
9. Duquesnoy RJ, Filip DJ, Aster RH: Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 50:407-412, 1977
10. Dunstan RA, Simpson MB: Heterogeneous distribution of antigens on human platelets demonstrated by fluorescence flow cytometry. Br J Haematol 61:603-609, 1985
11. Aster RH: Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 26:732-743, 1965
12. Pfisterer H, Thierfelder S, Stich W: ABO Rh blood groups and platelet transfusion. Blut 17:1-5, 1968
13. Kelton JG, Hamid C, Aker S, et al: The amount of blood group A substance on platelets is proportional to the amount in the plasma. Blood 59:980-985, 1982
14. Duquesnoy RJ, Anderson AJ, Tomasulo PA, et al: ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 54:595-599, 1979
15. Lee EJ, Schiffer CA: ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 29:384-389, 1989
16. Heal JM, Blumberg N, Masel D: An evaluation of cross-matching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 70:23-30, 1987
17. Heal JM, Rowe JM, Blumberg N: ABO and platelet transfusion revisited. Ann Hematol 66:309-314, 1993
18. Klumpp TR, Herman JH, Innis S, et al: Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 17:1035-1041, 1996
19. Lin Y, Callum JL, Coovadia AS, et al: Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion 42:166-172, 2002
20. Heal JM, Masel D, Rowe JM, et al: Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 85:566-572, 1993
21. Gorlin JB, ed. Standards for Blood Banks and Transfusion Services (20th Edition). Bethesda, MD. American Association of Blood Banks, 2000
22. Simon TL, Sierra ER: Concentration of platelet units into small volumes. Transfusion 24:173-175, 1984
23. Moroff G, Friedman A, Robkin-Kline L, et al: Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion 24:144-146, 1984
24. Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
25. Zoes C, Dube VE, Miller HJ, et al: Anti-A1 in the plasma of platelet concentrates causing a hemolytic reaction. Transfusion 17:29-32, 1977
26. McLeod BC, Sassetti RJ, Weens JH, et al: Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate. Scand J Haematol 28:193-196, 1982
27. Conway LT, Scott EP: Acute hemolytic transfusion reaction due to ABO incompatible plasma in a plateletapheresis concentrate. Transfusion 24:413-414, 1984
28. Pierce RN, Reich LM, Mayer K: Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion 25:60-62, 1985
29. Ferguson DJ: Acute intravascular hemolysis after a platelet transfusion. Can Med Assoc J 138:523-524, 1988
30. Reis MD, Coovadia AS: Transfusion of ABO-incompatible platelets causing severe haemolytic reaction. Clin Lab Haematol 11:237-240, 1989
31. Murphy MF, Hook S, Waters AH, et al: Acute haemolysis after ABO-incompatible platelet transfusions. Lancet 335:974-975, 1990
32. Mair B, Benson K: Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 38:51-55, 1998
33. McManigal S, Sims KL: Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction. Am J Clin Pathol 111:202-206, 1999
34. Larsson LG, Welsh VJ, Ladd DJ: Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion 40:902-906, 2000
35. Valbonesi M, De Luigi MC, Lercari G, et al: Acute intravascular hemolysis in two patients transfused with dry-platelet units obtained from the same ABO incompatible donor. Int J Artif Organs 23:642-646, 2000
36. Reducing Supernatant Plasma of Pooled Platelets Before Administration to ABO-incompatible Adult Recipients. CBBS, e-Network forum. Available at: http://www.cbbsweb.org/enet-PltpoolPlasma.html. Accessed May 12, 2002
37. Wallace EL, Churchill WH, Surgenor DM, et al: Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 38:625-636, 1998
38. Ervin DM, Young LE: Dangerous universal donors. I. Observation on destruction of recipient's A cells after transfusion of group O blood containing high titer of A antibodies of immune type no easily neutralizable by soluble A substance. Blood 5:61-73, 1950
39. Benjamin RJ, Mcgurk S, Ralston MS, et al: ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 39:179-187, 1999
40. Benjamin RJ, Antin JH: ABO-incompatible bone marrow transplantation: The transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion 39:1273-1274, 1999
41. Blumberg N, Heal JM, Hick GL, et al: Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 41:790-793, 2001
42. Marini AM, Matassi G, Raynal V, et al: The human Rhesus-associated RhAG protein and a kidney homologue promote ammonium transport in yeast. Nat Genet 26:341-344, 2000
43. Dunstan RA, Simpson MB, Rosse WF: Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion 24:243-246, 1984
44. Fijnheer R, Pietersz RNI, de Korte D, et al: Platelet activation during preparation of platelet concentrates: A comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 30:634-638, 1990
45. Lozano M, Estebanell E, Cid J, et al: Platelet concentrates prepared and stored under currently optimal conditions: Minor impact on platelet adhesive and cohesive functions after storage. Transfusion 39:951-959, 1999
46. Goldfinger D, McGinniss MH: Rh-incompatible platelet transfusions - Risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 284:942-944, 1971
47. Cid J, Ortin X, Elies E, et al: Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion 42:173-176, 2002
48. Lichtiger B, Surgeon J, Rhorer S: Rh-incompatible platelet transfusion therapy in cancer patients. A study of 30 cases. Vox Sang 45:139-143, 1983
49. Heim MU, Böck M, Kolb HJ, et al: Intravenous anti-D gammaglobulin for the prevention of Rhesus isoimmunization caused by platelet transfusion in patients with malignant diseases. Vox Sang 62:165-168, 1992
50. Atoyebi W, Mundy N, Croxton T, et al: Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Brit J Haematol 111:980-983, 2000
51. Molnar R, Johnson R, Sweat LT, et al: Absence of D alloimmunization in D-pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion 42:177-182, 2002
52. Pollack W, Ascari WQ, Crispen JF, et al: Studies on Rh prophylaxis. II. Rh immune prophylaxis after transfusion with Rh-positive blood. Transfusion 11:340-344, 1971
53. Urbaniak SJ, Robertson AE: A successful program of immunizing Rh-negative male volunteers for anti-D production using frozen/thawed blood. Transfusion 21:64-69, 1981
54. Bowman HS: Effectiveness of prophylactic Rh immunosuppression after transfusion with D-positive blood. Am J Obstet Gynecol 124:80-84, 1976
55. Mollison PL, Hughes-Jones NC, Lindsay M, et al: Suppression of primary RH immunization by passively-administered antibody. Experiments in volunteers. Vox Sang 16:421-439, 1969
56. Woodrow JC, Finn R, Krevans JR: Rapid clearance of Rh positive blood during experimental Rh immunisation. Vox Sang 17:349-361, 1969
57. Samson D, Mollison PL: Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology 28:349-357, 1975
58. Contreras M, Mollison PL: Failure to augment primary Rh immunization using a small dose of "passive" IgG anti-Rh. Br J Haematol 49:371-381, 1981
59. The Rh blood group system (and LW), in Mollison PL, Englefriet CP, Contreras M (eds): Blood Transfusion in Clinical Medicine (ed 10).London, Blackwell Science, 1997, pp 151-185
60. Shirey RS, King KE: Alloimmunization to blood group antigens, in Anderson KC, Ness PM (eds): Scientific Basis of Transfusion Medicine. Implications for Clinical Practice. Philadelphia, PA, 2000, pp 393-400
61. Gunson HH, Stratton F, Cooper DG, et al: Primary immunization of Rh-negative volunteers. Br Med J 1:593-595, 1970
62. Archer GT, Cooke BR, Mitchell K, et al: Hyper-immunisation des donneurs de sang pour la production des gammaglobulines anti-Rh(D). Rev Franç Transfus 12:341-350, 1969
63. Gunson HH, Stratton F, Phillips PK: The use of modified cells to induce an anti-Rh response. Br J Haematol 21:683-694, 1971
64. Baldwin ML, Ness PM, Scott D, et al: Alloimmunization to D antigen and HLA in D-negative immunosuppressed oncology patients. Transfusion 28:330-333, 1988
65. McLeod BC, Piehl MR, Sassetti RJ: Alloimmunization to RhD by platelet transfusion in autologous bone marrow transplant recipients. Vox Sang 59:185-189, 1990
66. Schonewille H, Haak HL, vanZijl AM: Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 39:763-771, 1999
67. Stern HS, Goodman S, Berger M: Experimental isoimmunization to hemoantigens in man. J Immunol 87:189-198, 1961
68. Stern K, Davidsohn I, Masaitis L: Experimental studies on Rh immunization. Am J Clin Pathol 26:833-943, 1956
69. Menitove JE: Immunoprophylaxis for D-patients receiving platelet transfusions from D+ donors. Transfusion 42:136-138, 2002
70. Zeiler T, Wittmann G, Zingsem J, et al: A dose of 100 IU intravenous anti-D gammaglobulin is effective for the prevention of Rh(D) immunisation after Rh(D)-incompatible single donor platelet transfusion. Vox Sang 66:243, 1994 (letter)
71. Ramsey G, Hahn LF, Cornell FW, et al: Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation 47:993-995, 1989
72. Cummins D, Contreras M, Amin S, et al: Red cell alloantibody development associated with heart and lung transplantation. Transplantation 59:1432-1435, 1995
73. Casanueva M, Valdes MD, Ribera MC: Lack of alloimmunization to D antigen in D-negative immunosuppressed liver transplant recipients. Transfusion 34:570-572, 1994
74. Pollack W, Gorman JG, Hager HJ, et al: Antibody-mediated immune suppression to the Rh factor: Animal models suggesting mechanism of action. Transfusion 8:134-145, 1968
75. Anderson B, Shad AT, Gootenberg JE, et al: Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD). Amer J Hematol 60:245-247, 1999
76. Sandler SG: Treating immune thrombocytopenic purpura and preventing Rh alloimmunization using intravenous rho (D) immune globulin. Transfus Med Rev 15:67-76, 2001
77. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340:1228-1233, 1999
78. Lawlor E, Columb G: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 341:762, 1999 (letter)
79. Bonis PA: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 341:763, 1999 (letter)
80. Birch GA, Alving BM: Plasma derivatives and adverse reactions, in Popovsky MA (ed): Transfusion Reactions (Ed 2). Bethesda, MD, AABB Press, pp 401-404
81. Bowman JM: The advantages of intravenous Rh-immune globulin. Clin Obstet Gynecol 25:341-347, 1982
82. Tarantino MD, Madden RM, Fennewald DL, et al: Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 134:21-26, 1999
83. Gaines AR: Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh-o(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 95:2523-2529, 2000
84. Imbach P, Kuhne T: Sequelae of treatment of ITP with anti-D (Rho) immunoglobulin. Lancet 356:447-448, 2000
85. Rushin J, Rumsey DH, Ewing CA, et al: Detection of multiple passively acquired alloantibodies following infusions of IVRH immune globulin. Transfusion 40:551-554, 2000
86. Wright J, Freedman J, Lim FC, et al: Crossmatch difficulties following the prophylactic use of Rh immune globulin. Can Med Assoc J 120:1235-1238, 1979
87. Stroncek DF, Procter JL, Moses L, et al: Intravenous Rh immune globulin prevents alloimmunization in D-granulocyte recipients but obscures the detection of an alloanti-K. Immunohematology 17:37-41, 2001
88. Rizk A, Gorson KC, Kenney L, et al: Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 41:264-268, 2001
89. Rivat L, Rivat C, Parent M, et al: Accident survenu après injection de gamma-globulines anti-Rh dû à présence d'anticorps anti-gamma A. Presse Med 78:2072, 1970
90. Branch DW, Guyman G, Scott JR: Failure to prevent rhesus immunisation with rhesus immune globulin after incompatible blood transfusion. Lancet 1:393-394, 1985
91. Bowman JM, Pollock JM: Failures of intravenous Rh immune globulin prophylaxis: An analysis of the reasons for such failures. Transfus Med Rev 1:101-112, 1987
92. Guide to the Preparation, Use and Quality Assurance of Blood Components. Strasbourg, France, Council of Europe Publishing, 2001